Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1\; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A\; MIM 300490) (Graham et al., 2006 [PubMed 16365421]).[supplied by OMIM, Mar 2008].. Additionally we are shipping LY9 Proteins (16) and LY9 Kits (10) and many more products for this protein.
Showing 10 out of 135 products:
Human Monoclonal LY9 Primary Antibody for FACS, IP - ABIN2479342
Antal: Global report on yaws and other endemic treponematoses. in The Southeast Asian journal of tropical medicine and public health 1987
Show all 4 Pubmed References
Human Monoclonal LY9 Primary Antibody for FACS - ABIN2479348
de la Fuente, Tovar, Villamor, Zapater, Pizcueta, Campo, Bosch, Engel: Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. in Blood 2001
Show all 4 Pubmed References
Human Monoclonal LY9 Primary Antibody for Func, ICC - ABIN1302635
Sintes, Romero, Marin, Terhorst, Engel: Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells. in Experimental hematology 2008
Show all 6 Pubmed References
Human Monoclonal LY9 Primary Antibody for Func, ICC - ABIN1303129
Romero, Benítez, March, Vilella, Miralpeix, Engel: Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). in Tissue antigens 2004
Show all 6 Pubmed References
Human Monoclonal LY9 Primary Antibody for CyTOF, FACS - ABIN445933
Martinez-Martin, Ramani, Hackney, Tom, Wranik, Chan, Wu, Paluch, Takeda, Hass, Clark, Gonzalez: The extracellular interactome of the human adenovirus family reveals diverse strategies for immunomodulation. in Nature communications 2016
Human Monoclonal LY9 Primary Antibody for FACS - ABIN4897608
Atanackovic, Panse, Hildebrandt, Jadczak, Kobold, Cao, Templin, Meyer, Reinhard, Bartels, Lajmi, Zander, Marx, Bokemeyer, Kröger: Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. in Haematologica 2011
Human Monoclonal LY9 Primary Antibody for Func, ICC - ABIN2749218
Bund, Mayr, Kofler, Hallek, Wendtner: Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells. in Experimental hematology 2006
Show all 5 Pubmed References
Authors make a strong correlation between induced SLAMF3 overexpression and the specific loss of MRP-1 (show MDM4 Antibodies) expression and its functionalities as a drugs resistance transporter.
the results presented here suggest that the tumor suppressor potential of SLAMF3 occurs through activation of Retinoblastoma protein that represses PLK1 (show PLK1 Antibodies).
study showed CD229 is overexpressed on the malignant plasma cells of patients across all types of plasma cell dyscrasias including multiple myeloma; CD229 is also expressed on the surface of a fraction of cells carrying the phenotype of chemotherapy-resistant and myeloma-propagating cells within the patients' bone marrow
the Val602 variant of the non-synonymous single nucleotide polymorphism (SNP) rs509749 in the SLAM (show SLAMF1 Antibodies) family member CD229 (Ly9, SLAMF3) has a two-fold lower affinity compared with the SLE-associated Met602 variant for the small adaptor protein SAP (show APCS Antibodies)
CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Results revealed that SLAMF3 plays a role during hepatitis C virus entry, likely by enhancing entry of viral particle within hepatocytes.
SLAMF3 is an inhibitor of hepatocellular carcinoma cell proliferation and tumor progression.
These results suggest a role for CD319 (show SLAMF7 Antibodies) and CD229 in the systemic lupus erythematosus disease process.
Data indicate that the dominance of the SLAMF3/SLAMF6 (show SLAMF6 Antibodies) pathway in inducing IL-17A (show IL17A Antibodies) production can be attributed to an increased nuclear abundance and recruitment of RORgammat to the IL17A (show IL17A Antibodies) promoter.
SLAMF3 and SLAMF6 (show SLAMF6 Antibodies) T cell surface expression and IL-17 (show IL17A Antibodies) levels significantly correlate with disease activity in systemic lupus erythematosus patients
Ly9/CD229 cell surface receptor emerges as a uniquely important element for modulating innate T cell function, acting as an inhibitory molecule that regulates invariant natural killer (NK)T cell development and innate-like CD8 (show CD8A Antibodies) T cell expansion.
Data show that defective tolerance was observed only in Fcgr2b-deficient mice with autoimmune-type Slam (show SLAMF1 Antibodies) family genes, indicating that epistatic effects of both genes are involved.
mouse novel Ly9 (show SLAMF7 Antibodies) is a new member of the expanding CD150 (show SLAMF1 Antibodies) family of cell surface receptors
CD229 is a self-ligand, interacting through its N-terminal V-like domain which contains three amino acid residues critical for the homophilic binding interaction.
CD229 is a pan (show SUPT6H Antibodies)-lymphocyte marker and indicate that mAbs against CD229 are able to down-modulate T-cell activation.
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1\; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A\; MIM 300490) (Graham et al., 2006
lymphocyte antigen 9
, T-lymphocyte surface antigen Ly-9
, T-lymphocyte surface antigen Ly-9-like
, t-lymphocyte surface antigen Ly-9-like
, SLAM family member 3
, cell surface molecule Ly-9
, signaling lymphocytic activation molecule 3